NCT06332092 - FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

FID007

Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.

Trial Locations (6)

33612

RECRUITING

Moffitt Cancer Center Magnolia Campus, Tampa

46804

RECRUITING

Fort Wayne Medical Oncology and Hematology, Fort Wayne

72703

RECRUITING

Highlands Oncology - North Hills, Fayetteville

75246

RECRUITING

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

75702

RECRUITING

Texas Oncology - Northeast Texas Cancer & Research Institute, Tyler

90033

RECRUITING

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles